TFS Capital’s Integra LifeSciences IART Stock Holding History

TFS Capital’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-20,632	Closed	-$885K	–	749
2016 Q4	$885K	Buy	+20,632	New	+$839K	0.24%	155
2015 Q4	–	Sell	-60,696	Closed	-$1.81M	–	811
2015 Q3	$1.81M	Sell	60,696 -5,789	-9%	-$181K	0.17%	186
2015 Q2	$1.83M	Buy	+66,485	New	+$1.77M	0.18%	168
2015 Q1	–	Sell	-27,870	Closed	-$618K	–	1029
2014 Q4	$618K	Buy	+27,870	New	+$565K	0.06%	520

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TFS Capital's IART Position: Q1 2017 in Review

TFS Capital sold out of Integra LifeSciences (IART) in Q1 2017, closing a stake of 20,632 shares — an estimated $885K sold.

TFS Capital first reported a position in IART in Q4 2014 and held it in 4 quarters. The position peaked at $1.83M in Q2 2015. 236 funds tracked by Wall St. Rank hold IART as of Q1 2017.

TFS Capital reported no remaining Integra LifeSciences position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 20,632 Integra LifeSciences shares in Q1 2017, an estimated $885K.
TFS Capital first reported a position in Integra LifeSciences in Q4 2014 and held it in 4 quarters.
TFS Capital's Integra LifeSciences position peaked at $1.83M in Q2 2015.
236 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.